Agilent Buys Medical Instruments Maker Biocare for $950 Million

March 9, 2026, 6:01 AM UTC

Agilent Technologies Inc. agreed to acquire privately held Biocare Medical, which makes instruments and materials used in cancer research, in an all-cash transaction valued at $950 million.

Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group, according to a statement reviewed by Bloomberg News. The deal is expected to be accretive earnings per share about 12 months after it closes, and will “accelerate innovation and support long-term value creation for our shareholders,” Agilent Chief Executive Officer Padraig McDonnell said in the statement.

With more than 300 specialized antibodies, Biocare, based in the San Francisco Bay ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.